CX Stock Forecast & Price Target

Cemex is well positioned because its earnings quality, cash generation, and balance-sheet discipline are improving structurally rather than cyclically, with leverage down to 2.08x, net interest expense falling from about 30% of EBITDA in 2019 to roughly 16% in 2025, and FCF conversion improving to around 33% from 28% in 2019. Management’s Project Cutting Edge and broader capital allocation reset are driving durable cost savings, including an increased savings target of $475m, while full-year EBITDA guidance has been raised to 16-17% year-on-year growth and 2026 energy costs are now expected to rise only low single digits. The company also benefits from stronger operating momentum in Mexico, where margins expanded by 480bps YoY in Q2'26 and volume growth is being supported by social housing and self-construction, while lower expected interest expense of about $455m and disciplined capex/intangibles spending should support further upside in free cash flow.

Cemex is facing a negative fundamental setup because its apparent U.S. weakness is not yet fully demand-led but still reflects margin pressure from weather disruptions in Texas/Mid-South, temporary third-party aggregate purchases in Arizona, and elevated cement imports, all of which can keep profitability volatile even if underlying volumes improve. The company’s heavy concentration in North America means its performance remains highly exposed to U.S. construction cycles, residential real estate softness, hurricane risk in H2, and exchange-rate sensitivity in Mexico, where a MXN 1.00 move per USD can shift EBITDA by about US$85M and Mexico contributes roughly 40% of consolidated EBITDA. Although Cemex has strong scale with 81 million metric tons of annual cement capacity and the ability to post FY26 EBITDA growth of 17.5% under favorable assumptions, the need to revise U.S. and Europe estimates more conservatively and the risk that slower capital deployment in North America could pressure growth make the outlook fundamentally cautious.